Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia

Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the College of Physicians and Surgeons--Pakistan 2008-03, Vol.18 (3), p.176
Hauptverfasser:	Khan, Khurshid Ahmed, Junaid, Ayesha, Siddiqui, Nauman Saleem, Mukhtar, Khalida, Siddiqui, Saleem
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Benzamides Bone Marrow Diseases - chemically induced Fatal Outcome Fusion Proteins, bcr-abl Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Male Middle Aged Piperazines - adverse effects Piperazines - therapeutic use Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - adverse effects Pyrimidines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.
ISSN:	1022-386X